ASX Filings

Opthea presents Ph1/2a wAMD data at Retina Society Meeting

September 14, 2018

Opthea Receives Positive Safety Review for Ph2b wAMD Trial

September 5, 2018

Opthea Appendix 4E and Annual Report 2018

August 28, 2018

Appendix 4G and Corporate Governance Statement 2018

August 28, 2018

Appendix 3B

August 6, 2018

Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME

July 30, 2018

Opthea Meets Primary Safety Objective in DME Phase 1b trial

July 26, 2018

Opthea reaches mid-way in recruitment for Ph2b wAMD trial

July 2, 2018

Appendix 3B

June 27, 2018

Change in substantial holding

May 30, 2018